Venetoclax Makes Inroads Into More Hematologic Setting

Venetoclax Makes Inroads Into More Hematologic Setting Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention mediante 2020 for positive reports from phase 3 clinical trials exploring its use per acute myeloid leukemia and multiple myeloma. Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 …

Venetoclax Makes Inroads Into More Hematologic Setting Leer más »